GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (LTS:0RN4) » Definitions » Interest Expense

Oncopeptides AB (LTS:0RN4) Interest Expense : kr-2.09 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Oncopeptides AB's interest expense for the three months ended in Dec. 2024 was kr 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was kr-2.09 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Oncopeptides AB's Operating Income for the three months ended in Dec. 2024 was kr -83.33 Mil. Oncopeptides AB's Interest Expense for the three months ended in Dec. 2024 was kr 0.00 Mil. GuruFocus does not calculate Oncopeptides AB's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Oncopeptides AB Interest Expense Historical Data

The historical data trend for Oncopeptides AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Interest Expense Chart

Oncopeptides AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.49 -0.95 -0.88 -5.79 -0.71

Oncopeptides AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.09 - - -

Oncopeptides AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncopeptides AB  (LTS:0RN4) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oncopeptides AB's Interest Expense for the three months ended in Dec. 2024 was kr0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was kr-83.33 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was kr121.89 Mil.

Oncopeptides AB's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Oncopeptides AB's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Oncopeptides AB Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines

No Headlines